Pfizer won U.S. approval for its drug tafamidis to treat a rare heart disease, but whether the treatment that costs $225,000 year will be covered by heath insurers and employers remains unclear.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,